IQVIA Holdings Inc. (0JDM.L)
USD 147.96
(3.19%)
USD 147.96
(3.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.25 Billion USD | 9.19% |
| 2022 | 2.88 Billion USD | 4.41% |
| 2021 | 2.74 Billion USD | 31.39% |
| 2020 | 2.06 Billion USD | 1.95% |
| 2019 | 1.88 Billion USD | 7.53% |
| 2018 | 1.88 Billion USD | 7.9% |
| 2017 | 1.65 Billion USD | 60.32% |
| 2016 | 906 Million USD | 39.46% |
| 2015 | 756.19 Million USD | 10.48% |
| 2014 | 711.36 Million USD | 24.62% |
| 2013 | 541.54 Million USD | 13.06% |
| 2012 | 500.08 Million USD | 11.48% |
| 2011 | 385.74 Million USD | -5.4% |
| 2010 | 467.37 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 797 Million USD | -2.33% |
| 2024 Q1 | 788 Million USD | -9.12% |
| 2024 Q2 | 817 Million USD | 6.52% |
| 2023 Q4 | 875 Million USD | 2.1% |
| 2023 Q3 | 857 Million USD | 4.13% |
| 2023 Q1 | 773 Million USD | 0.0% |
| 2023 Q2 | 823 Million USD | 6.47% |
| 2023 FY | - USD | 9.19% |
| 2022 Q3 | 720 Million USD | 3.45% |
| 2022 Q1 | 748 Million USD | 1.91% |
| 2022 Q4 | 773 Million USD | 7.36% |
| 2022 Q2 | 696 Million USD | -6.95% |
| 2022 FY | - USD | 4.41% |
| 2021 Q1 | 712 Million USD | 10.73% |
| 2021 Q2 | 663 Million USD | -6.88% |
| 2021 Q3 | 704 Million USD | 6.18% |
| 2021 FY | - USD | 31.39% |
| 2021 Q4 | 734 Million USD | 4.26% |
| 2020 Q1 | 538 Million USD | -2.0% |
| 2020 Q4 | 643 Million USD | 18.85% |
| 2020 Q2 | 419 Million USD | -22.12% |
| 2020 Q3 | 541 Million USD | 29.12% |
| 2020 FY | - USD | 1.95% |
| 2019 Q1 | 526 Million USD | 3.95% |
| 2019 FY | - USD | 7.53% |
| 2019 Q2 | 500 Million USD | -4.94% |
| 2019 Q3 | 525 Million USD | 5.0% |
| 2019 Q4 | 549 Million USD | 4.57% |
| 2018 Q1 | 489 Million USD | 0.41% |
| 2018 FY | - USD | 7.9% |
| 2018 Q4 | 506 Million USD | 9.52% |
| 2018 Q3 | 462 Million USD | -6.85% |
| 2018 Q2 | 496 Million USD | 1.43% |
| 2017 Q2 | 443 Million USD | 5.98% |
| 2017 Q1 | 418 Million USD | -10.23% |
| 2017 Q4 | 487 Million USD | 5.41% |
| 2017 Q3 | 462 Million USD | 4.29% |
| 2017 FY | - USD | 60.32% |
| 2016 Q1 | 209.78 Million USD | 8.12% |
| 2016 Q3 | 198.02 Million USD | -6.39% |
| 2016 Q2 | 211.53 Million USD | 0.83% |
| 2016 FY | - USD | 39.46% |
| 2016 Q4 | 465.63 Million USD | 135.14% |
| 2015 FY | - USD | 10.48% |
| 2015 Q4 | 194.02 Million USD | -9.32% |
| 2015 Q3 | 213.96 Million USD | 16.01% |
| 2015 Q2 | 184.43 Million USD | 1.0% |
| 2015 Q1 | 182.6 Million USD | 11.24% |
| 2014 Q4 | 164.14 Million USD | -13.38% |
| 2014 Q3 | 189.49 Million USD | 11.64% |
| 2014 Q1 | 177.51 Million USD | 8.98% |
| 2014 FY | - USD | 24.62% |
| 2014 Q2 | 169.73 Million USD | -4.38% |
| 2013 Q3 | 157.67 Million USD | 28.23% |
| 2013 Q4 | 162.88 Million USD | 3.3% |
| 2013 FY | - USD | 13.06% |
| 2013 Q1 | 144.49 Million USD | 13.3% |
| 2013 Q2 | 122.96 Million USD | -14.9% |
| 2012 Q1 | 117.79 Million USD | 0.0% |
| 2012 Q3 | 131.42 Million USD | -8.32% |
| 2012 Q4 | 127.53 Million USD | -2.96% |
| 2012 FY | - USD | 11.48% |
| 2012 Q2 | 143.34 Million USD | 21.7% |
| 2011 FY | - USD | -5.4% |
| 2010 FY | - USD | 0.0% |
| 2001 Q3 | 716 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 69.852% |
| Dynavax Technologies Corporation | 9.66 Million USD | -33585.082% |
| Illumina, Inc. | -608 Million USD | 635.526% |
| Biogen Inc. | 2.37 Billion USD | -36.979% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 825.146% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | -179.714% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 841.355% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | -3213.59% |
| Waters Corporation | 1.02 Billion USD | -218.513% |
| Perrigo Company plc | 646.2 Million USD | -403.869% |
| uniQure N.V. | -253.1 Million USD | 1386.448% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 1042.498% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 3636.094% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 1324.074% |
| bluebird bio, Inc. | -167.16 Million USD | 2047.823% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 2867.531% |
| Imunon, Inc. | -20.78 Million USD | 15767.197% |
| Myriad Genetics, Inc. | -67.8 Million USD | 4902.36% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | -682.504% |
| Nektar Therapeutics | -243.1 Million USD | 1439.328% |
| Editas Medicine, Inc. | -163.11 Million USD | 2096.113% |
| Verastem, Inc. | -83.16 Million USD | 4015.061% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 128.87% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 7427.277% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 3237.043% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 8833.203% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | -949.361% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 3824.25% |
| Evolus, Inc. | -41.81 Million USD | 7887.611% |
| Adicet Bio, Inc. | -136.53 Million USD | 2484.737% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 3800.631% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 30.042% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 2269.105% |
| FibroGen, Inc. | -261.4 Million USD | 1345.577% |
| Agilent Technologies, Inc. | 1.67 Billion USD | -94.156% |
| OPKO Health, Inc. | -65.51 Million USD | 5069.778% |
| Homology Medicines, Inc. | -47.75 Million USD | 6917.991% |
| Geron Corporation | -174.78 Million USD | 1962.892% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 1527.313% |
| Exelixis, Inc. | 196.6 Million USD | -1556.138% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 3329.294% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 5939.73% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 743.078% |
| Zoetis Inc. | 3.68 Billion USD | 11.642% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 1547.169% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 6538.345% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 29.297% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 9123.89% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 1515.591% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -2905.797% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | -620.438% |
| Blueprint Medicines Corporation | -474.61 Million USD | 786.034% |
| Insmed Incorporated | -654.73 Million USD | 597.297% |
| TG Therapeutics, Inc. | 26.1 Million USD | -12375.096% |
| Incyte Corporation | 919.42 Million USD | -254.134% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 744.37% |